Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Dry Age Related Macular Degeneration (AMD) Market?
The market size for dry age related macular degeneration (AMD) has seen substantial growth recently. The market is predicted to increase from $4.49 billion in 2024 to $4.90 billion in 2025, with a compound annual growth rate (CAGR) of 9.1%. Factors contributing to this growth during the historical duration include an aging population, a higher incidence of chronic illnesses, enhanced knowledge about eye health, an increase in clinical trials centered on dry AMD, and a rise in demand for less invasive treatment methods.
What Growth Rate Is Forecasted for the Dry Age Related Macular Degeneration (AMD) Market by 2029?
There is an anticipation for the market size of dry age related macular degeneration (AMD) to witness robust expansion in the upcoming years. By 2029, it is predicted to reach a value of $6.86 billion, with a compound annual growth rate (CAGR) of 8.8%. The substantial growth within the forecast period is likely to occur due to the emergence of unique therapies, escalated health expenditure, an upsurge in the use of laser photocoagulation therapy, breakthroughs in genetic studies, and a growing emphasis on personalized medicine. Predominant trends for the forecasted period include progress in diagnostic technologies, increased adoption of teleophthalmology, high-tech treatments, product clearances, and the introduction of new products.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21176&type=smp
Which Key Companies Are Shaping the Future of the Dry Age Related Macular Degeneration (AMD) Market?
Major companies operating in the dry age related macular degeneration (AMD) market are F Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Amgen Inc., Biogen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Lupin Ltd., Santen Pharmaceuticals Inc., Biocon Ltd., Alimera Sciences Inc., Apellis Pharmaceuticals Inc., Belite Bio Inc., Axol Bioscience Ltd., Alkeus Pharmaceuticals Inc., Kubota Holdings Co., Ribomic Inc., Eyestem Research Pvt. Ltd., LumiThera Inc., Adverum Biotechnologies Inc.
Which Factors Are Driving Demand in the Dry Age Related Macular Degeneration (AMD) Industry?
The rise in the elderly population is anticipated to spur the growth of the dry age-related macular degeneration (AMD) market in the future. The term “geriatric population” specifically refers to individuals who are 65 years or older. The amplified number of elderly individuals can be attributed to various factors, including progress in medical technology, improved handling of chronic diseases, longer life expectancy, and enhanced geriatric care. Dry age-related macular degeneration (AMD) comes to the aid of the geriatric population by offering specific treatment strategies and control methods designed to decelerate the disease’s progression, maintain their vision, and enhance their quality of life. For example, research published by the National Council on Aging, a U.S-based entity, in June 2024, indicates that there were about 57.8 million adults over 65 in 2022, making up 17.3% of the entire U.S. population. This presented a rise from the 16.9% reported in 2021. Consequently, the escalating geriatric population is set to boost the growth of the dry age-related macular degeneration (AMD) market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21176&type=smp
How Is the Dry Age Related Macular Degeneration (AMD) Market Segmented by Several Divisions?
The dry age related macular degeneration (AMD) market covered in this report is segmented –
1) By Stages: Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration
2) By Age Group: Above 75 Years, Above 60 Years, Above 40 Years
3) By Route Of Administration: Oral, Injectables
4) By End Users: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes
Subsegments:
1) By Early Age-Related Macular Degeneration: Drusen Accumulation, Retinal Pigment Epithelium Changes
2) By Intermediate Age-Related Macular Degeneration: Larger Drusen Deposits, Increased Pigmentary Abnormalities
3) By Late Age-Related Macular Degeneration: Geographic Atrophy, Central Vision Loss
What are the Emerging Market Trends Driving the Growth of the Dry Age Related Macular Degeneration (AMD) Industry?
In the dry age-related macular degeneration (AMD) market, key players are centering their efforts on creating and implementing advanced technologies and treatments like light delivery systems. These are specifically aimed at the activation and targeting of retinal cells, with the hope of slowing down the advancement of the disease. Light delivery systems are essentially technological devices made to convey light strategically for therapeutic uses, particularly for medical treatments. As an exemplification, LumiThera Inc., a medical device establishment in the US, rolled out photobiomodulation (PBM) for dry AMD using the Valeda Light Delivery System in January 2024. This therapy, the first of its kind authorized by the FDA, was developed to combat vision loss in patients afflicted by dry AMD, a condition that presently has very few treatment alternatives. LumiThera started the EUROLIGHT registry study to compile long-term data on the effects of the Valeda system on treated patients. The Valeda system is equipped with a multi-wavelength light delivery function that operates on three specific wavelengths (590 nm, 660 nm, and 850 nm). This non-intrusive treatment can be applied either through a closed or open eyelid, usually necessitating nine sessions over a span of three to four weeks.
Access The Full Report Here:
Which Regions Are Driving Growth in the Dry Age Related Macular Degeneration (AMD) Market?
North America was the largest region in the dry age-related macular degeneration (AMD) market in 2024. The regions covered in the dry age related macular degeneration (AMD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21176
This Report Delivers Insight On:
1. How big is the dry age related macular degeneration (amd) market, and how is it changing globally?
2. Who are the major companies in the dry age related macular degeneration (amd) market, and how are they performing?
3. What are the key opportunities and risks in the dry age related macular degeneration (amd) market right now?
4. Which products or customer segments are growing the most in the dry age related macular degeneration (amd) market?
5. What factors are helping or slowing down the growth of the dry age related macular degeneration (amd) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model